Partnerships

Discover our academic or industrial partnership opportunities

Revolutionising Personalised Medicine with Companion Diagnostics

Companion Diagnostics (CDx) is the foundation of personalised medicine, where specific in vitro diagnostic tests can identify biomarkers that predict whether a patient will respond to a particular treatment. Using these biological signatures to identify patients likely to benefit from certain therapies has significantly accelerated the pace of drug development and approval.

Our state-of-the-art bio-imaging platform, QF-Pro®, uniquely quantifies functional protein events with less than 10nm resolution using an enhanced Förster Resonance Energy Transfer-Fluorescence Lifetime Imaging Microscopy (FRET-FLIM) approach. Validated in clinical settings, QF-Pro® accurately predicts patient responses to targeted treatments, facilitating biomarker-guided drug development and clinical trials, and enabling the creation of robust CDx solutions.

HAWK Biosystems CDx Clinical Applications

Immune Checkpoint Inhibitors (ICIs)

If you are developing ICIs for different tumors, we can significantly improve the prognosis and predictive response of patients.

ICIs, like PD-1/PD-L1, help the immune system target cancer cells. However, nowadays only 12-20% of solid tumor patients respond to these therapies, partly due to the lack of reliable biomarkers for predicting patient response. By quantifying specific protein-protein interactions within tumor tissue samples, we can identify patients likely to respond better to ICIs.

We have validated the clinical implication of PD-1/PD-L1 protein interaction in the context of non-small cell lung cancer (NSCLC). QF-Pro® enhanced patient stratification, tripling response rates, and doubling overall survival compared to the current clinical gold-standard, PD-L1 TPS score.

We have validated the following immune checkpoint interactions: PD-1/PD-L1, TIGIT/CD155, TIM-3/Gal9, LAG-3/MHCII, CTLA-4/CD80, and VISTA/VISG3.

Post-Translational Modifications (PTMs)

Gain valuable insights into intracellular signaling pathway dynamics and design small molecule therapeutics.

PTMs like phosphorylation, lipidation, acetylation, methylation, and glycosylation regulate oncoprotein activity. These modifications act as molecular switches, controlling cell transitions from rest to proliferation. Without proper regulation, PTMs can enhance oncoprotein functionality, driving cancer progression.

QF-Pro® enables spatial mapping of PTMs, allowing the quantification of functional protein states within samples. In a case study, QF-Pro® measured the activation state of the oncoprotein Akt/PKB in clear cell renal cell carcinoma (ccRCC), predicting overall survival. Patients with higher Akt/PKB activation had poorer survival, demonstrating the value of functional spatial proteomics in mapping prognostic biomarkers.

We have validated various PTM biomarkers, including: Akt/PKB activation state (pT308), and .–STAT3 activation state (pY705 or pS727).

Protein-Protein Interactions (PPIs)

Investigate new routes to elucidate biologically relevant biomarkers.

QF-Pro® technology enables the investigation of key PPIs involved in cancer and other diseases. By quantifying these interactions, we can uncover novel biomarkers for patient stratification and treatment response.

We have validated the following PPIs biomarkers: HER2/HER3 interaction state, and PKB/PDK1 interaction state.

DNA-Protein Interactions (DPIs)

Quantifying DNA-protein interactions can add significant value to R&D and clinical development.

QF-Pro® platform can map and quantify interactions between DNA and proteins, providing insights into gene regulation mechanisms and potential therapeutic targets.

Join HAWK Biosystems CDx Partnering Solution

From initial biomarker discovery to commercialisation, we offer end-to-end CDx partnering solutions for our biopharmaceutical customers. Our collaborative approach ensures that we work hand-in-hand with our partners to build a drug-diagnostic co-development model based on each customer’s specific requirements.

Drug Development Pathway:

Our CDx Developing Services:

Why partner with HAWK Biosystems CDx?

Enhanced patient stratification and outcomes

Identify patients who will benefit most from your therapy minimising adverse events and improving overall patient outcomes.

Increased clinical trial success rates

By selecting the right patients, reduce trial costs and duration.

Accelerate regulatory approval

CDx provides clear evidence of targeted efficacy and safety, potentially speeding up FDA and EMA approval processes.

Unique market positioning

CDx differentiates your therapy by emphasising the precision and personalised approach.

Cost savings for healthcare providers

Optimise treatment plans, reducing unnecessary treatments and associated costs.

Working with some of the top 10 pharmaceutical companies

Collaborations

At HAWK Biosystems, we thrive on research partnerships and are constantly seeking to work in tandem with clinicians, researchers and academics alike. We have undertaken multiple partnerships with a range of universities and research organisations across several continents.

HAWK Biosystems are constantly striving to inspire, train and promote young scientists in a multidisciplinary manner that spans both academia and industry. We therefore host masters’ placements and PhD students from a range of different academic backgrounds. If you are interested in joining the HAWK Biosystems team, get in touch today.

Why Hawk?

Learn why we are the best choice for exploring protein functions in spatial biology. Our extensive expertise, combined with the unrivalled and precision of QF-Pro® make us the best choice for advancing your research.

Validated Biomarkers

Find out more about the wide range of validated QF-Pro® assays that we offer, ranging from immune checkpoint interactions to dimerisations or kinase activation states. Our flexible technology can be applied to quantify the function of any biomarker in any disease setting.

Our company

Find out everything behind HAWK Biosystems and the company’s culture. Learn about our core mission, vision, and values. Hear testimonials from our current employees to see how our company fosters an environment of opportunity and innovation.

PYME INNOVADORA

Válido hasta el 20 de agosto de 2027